Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Semaglutide (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 7
- Sponsors Novo Nordisk
- 01 Feb 2018 Results from this trial published in The Lancet Diabetes & Endocrinology, according to a Novo NOrdisk media release.
- 01 Feb 2018 Results presented in a Novo Nordisk media release.
- 01 Feb 2018 Primary endpoint (Change in HbA1c) has been met, according to a Novo Nordisk media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History